Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2013 Jul 26;12(10):2200–2212. doi: 10.1158/1535-7163.MCT-13-0095

Figure 1.

Figure 1

Inhibition of EGFR by erlotinib downregulates PTPMeg2 in association with activation of the STAT3/Bcl2/Bcl-XL pathway in lung cancer HCC827 cells. A, HCC827 cells were treated with increasing concentrations of erlotinib (Erlo) for 48h. pEGFR, PTPMeg2, pSTAT3, Bcl2, Bcl-XL, etc., were analyzed by Western blot. B, HCC827 cells were treated with erlotinib (0.1 μM) for various times. Levels of Bcl2 or Bcl-XL mRNA were analyzed by RT-PCR.